Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof Grant US-11866434-B2 United States of America 09 Jan 2024
Salts and crystalline forms of a PD-1/PD-L1 inhibitor Grant US-11866451-B2 United States of America 09 Jan 2024
Process of preparing a PD-1/PD-L1 inhibitor Grant US-11780836-B2 United States of America 10 Oct 2023
ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOF Application EP-3823991-A4 European Patent Office 03 Aug 2022
Pyrido[3,2-d]pyrimidine compounds as immunomodulators Grant US-11401279-B2 United States of America 02 Aug 2022
Immunomodulator compounds and methods of use Grant US-10806785-B2 United States of America 20 Oct 2020
Anti-DLL3 antibody drug conjugates for treating cancer Grant US-10478509-B2 United States of America 19 Nov 2019
Anti-DLL3 antibodies and drug conjugates for use in melanoma Grant US-10308721-B2 United States of America 04 Jun 2019
Anti-DLL3 antibody drug conjugates for treating cancer Grant US-10137204-B2 United States of America 27 Nov 2018
Site-specific antibody conjugation methods and compositions Grant US-10035853-B2 United States of America 31 Jul 2018
Anti-DLL3 antibody drug conjugates and methods of use Grant US-9937268-B2 United States of America 10 Apr 2018
Methods of delivering DLL3 antibody drug conjugates Grant US-9931421-B2 United States of America 03 Apr 2018
Methods of making DLL3 antibody drug conjugates Grant US-9931420-B2 United States of America 03 Apr 2018
Methods of delivering DLL3 antibody drug conjugates Grant US-9878053-B2 United States of America 30 Jan 2018
Kits containing DLL3 antibody drug conjugates Grant US-9861708-B2 United States of America 09 Jan 2018
HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Application WO-2017205464-A1 World Intellectual Property Organisation (WIPO) 30 Nov 2017
Anti-DLL3 antibody drug conjugates for treating cancer Grant US-9775916-B1 United States of America 03 Oct 2017
Methods of making DLL3 antibody drug conjugates Grant US-9764042-B1 United States of America 19 Sep 2017